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Suppression of KRas-mutant cancer through the
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No effective targeted therapies exist for cancers with somatic KRAS mutations. Here we
develop a synthetic lethal chemical screen in isogenic KRAS-mutant and wild-type cells to
identify clinical drug pairs. Our results show that dual inhibition of polo-like kinase 1 and
RhoA/Rho kinase (ROCK) leads to the synergistic effects in KRAS-mutant cancers.
Microarray analysis reveals that this combinatory inhibition significantly increases
transcription and activity of cyclin-dependent kinase inhibitor p21WAF1/CIP1, leading to specific
G2/M phase blockade in KRAS-mutant cells. Overexpression of p21WAF1/CIP1, either by cDNA
transfection or clinical drugs, preferentially impairs the growth of KRAS-mutant cells,
suggesting a druggable synthetic lethal interaction between KRAS and p21WAF1/CIP1.
Co-administration of BI-2536 and fasudil either in the LSL-KRASG12D mouse model or in a
patient tumour explant mouse model of KRAS-mutant lung cancer suppresses tumour growth
and significantly prolongs mouse survival, suggesting a strong synergy in vivo and a potential
avenue for therapeutic treatment of KRAS-mutant cancers.
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O
ncogenic mutations in the GTPase protein RAS (NRAS,
KRAS and HRAS) occur in up to a third of all human
cancers1–3. KRAS is the principal isoform of RAS, and
somatic mutations in KRAS are associated with over 21% of all
cancers; a particularly high frequency of KRASmutations is observed
in pancreatic, colorectal and lung cancers, three of the top four
leading causes of new cancer deaths4. KRAS-mutant tumours exhibit
oncogene addiction5,6, and KRAS seems to be an ideal target for
cancer therapeutics. However, 30 years after its characterization,
mutant KRAS still poses a significant therapeutic challenge and is
associated with poor prognosis and resistance to existing therapies7,8.
Alberto and colleagues recently drew an analogy between the
challenges of tackling mutant KRAS and climbing Mount Everest8.
The lack of suitable small-molecule binding sites in its protein
structure makes RAS difficult to target1. Partly due to this issue, direct
pharmacologic targeting of activated RAS protein with small
molecules seems to be an impossible task, although small
molecules that bind to allosteric regulatory sites on KRAS (G12C)
have shown preclinical benefits9. To overcome this limitation,
investigators have explored other potential therapeutic approaches,
such as indirectly targeting mutant KRAS, developing drugs to inhibit
downstream KRAS effectors or using unbiased searches for targets
that are synthetically lethal with mutant KRAS3,10.
The majority of the efforts over the past few years have aimed
at developing drugs that target KRAS downstream effectors.
However, targeting a single KRAS effector or a combination of
multiple downstream effectors showed modest or no clinical
responses against mutant KRAS cancers in early-phase clinical
trials8,11–13; this is probably because KRAS activates multiple
parallel networks and is subject to uncontrolled signalling
feedback. Recent studies have taken advantage of KRAS
oncogene addiction to search for synthetic lethal partners of
mutant KRAS. Several genome-wide RNA interference (RNAi)
screens and other technologies have identified a list of candidate
genes, including TANK-binding kinase 1 (TBK1)14, serine-
threonine kinase STK33 (ref. 15) and heat-shock protein 90
(HSP90; the inhibition of HSP90 involves the degradation of
STK33)16, polo-like kinase 1 (PLK1)17,18, cyclin-dependent kinase
4 (CDK4)19, transcription factor (TF) GATA2 (refs 20,21),
evolutionarily conserved gene enhancer of rudimentary
homologue (ERH)18, transforming growth factor b-activated
kinase 1 (TAK1)22, anti-apoptotic BH3 family member BCL-XL23,
mitotic regulators17,21, proteasome and topoisomerase
components17,20,21 and genes that are involved in glucose
metabolism (for example, hexokinase 2)24. Although only a
modest overlap was found among these identified candidates
(probably due to differences in cell types and experimental
setting) and some candidate genes lack effective inhibitors (for
example, the TF GATA2), the strategy aimed at synthetic lethality
did open up a new avenue to treat KRAS-driven cancers. To
advance the discovery of drugs against mutant KRAS tumours,
synthetic lethal chemical screens have emerged and represent a
direct and complementary approach to identifying drugs that
target the essential signalling networks for the growth of KRAS-
mutant tumours. More importantly, such an approach could also
provide immediately usable translational therapeutic strategies by
identifying drugs that are already available in clinic.
To achieve more potent efficacy and less toxicity, a ‘cocktail’ of
drugs is now often given to avoid primary or acquired resistance
to single agents after a period of administration25, especially in
KRAS-mutant cancers23,26. The combined inhibition of KRAS
downstream effectors has shown toxicity and disappointing
efficacy in clinical testing27, therefore searching for novel and
clinically applicable anti-RAS drug pairs is of great importance.
In this study, we employ synthetic lethal drug screening plus a
combinatorial strategy using a panel of clinical agents. We find
that drugs targeting KRAS synthetic lethal genes account for a
large proportion of observed synergies and identify several novel
and unique genotype-selective synergistic drug pairs within the
panel. We further confirm the selective anti-RAS efficacy of
combined inhibition of PLK1 and Rho signalling in vitro and
in vivo. This combination increases the expression of
p21WAF1/CIP1 in KRAS-mutant cells in a p53-independent manner.
Notably, the overexpression of p21WAF1/CIP1 selectively kills cells
harbouring KRAS mutations while sparing wild-type cells. Our
findings suggest a drug combination that disrupts KRAS synthetic
lethal dependency, which could be therapeutically exploited to
inhibit KRAS-driven cancers.
Results
A synthetic lethal drug screen. To identify innovative drug
combinations to treat KRAS-mutant cancers, we performed a
synthetic lethal chemical screen. We evaluated the impact of the
KRAS-mutant genotype on a panel of agents that directly or
indirectly targeted RAS effector pathways and therefore had a
potential for synthetic lethal interaction with mutant KRAS
(Supplementary Table 1). Because we aimed to employ synthetic
lethal drug screening plus a combinatorial strategy, we assume
that the drugs targeting pathways upstream of RAS, downstream
of RAS or mutant RAS-dependent pathways may coordinate with
each other to produce more profound actions to kill KRAS-
mutant tumours by unrivalled mechanisms or signalling
crosstalk.
We performed the primary screening in immortalized human
ovarian surface epithelial cells (T29) and their transformed
isogenic counterparts that expressed mutationally activated
KRASV12 (designated T29Kt1)28. The concentrations required
to inhibit 50% of cell growth (half-maximal inhibitory
concentration, IC50) were calculated (Supplementary Table 1).
Most inhibitors showed selectivity for the KRAS-mutant genotype
as a single agent (for example, BI-2536), but several agents elicited
incomplete growth inhibition. The combinatorial screening of
these drugs was then performed to achieve full growth inhibition
and increase the differential sensitivity between KRAS-mutant
and wild-type cells. When tested, T29Kt1 cells were not
preferentially sensitive to gefitinib, a small-molecule inhibitor of
the epidermal growth factor receptor (EGFR), as the IC50’s in
T29Kt1 and T29 cells were rather comparable. These results were
consistent with the reports that tumours bearing activating
mutations within KRAS are highly negative or resistant to anti-
EGFR therapy29,30.
To explore the most effective drug combinations, we generated
a mixture of two drugs at their equipotent ratio (at the ratio of
their IC50’s) and treated T29Kt1 cells with serial dilutions of the
mixture (1:1, 1:2, 1:4 and 1:8), resulting in four pairwise
combinations per drug pair in parallel with single-agent controls.
The combination index (CI) was calculated using CalcuSyn
software (Version 2; Biosoft) to analyse the interaction (synergis-
tic, additive or antagonistic) (Fig. 1a). The combinations were
often antagonistic (62%) in T29Kt1 cells, while only 28%
(synergism 18% and moderate synergism 10%) of the drug pairs
showed a pattern of extensive synergies (Fig. 1a, left). To identify
genotype differences in the synergistic drug pairs (CIo1), we
categorized the inhibitors as either targeting synthetic lethal genes
or other genes. Inhibitors of synthetic lethal genes contributed to
over 70% of the synergies observed (Fig. 1a, right), indicating that
synthetic lethal genes play an indispensable role in the growth of
KRAS-mutant cancers and represent applicable targets for
treatment. We analysed the Fa (fraction affected by the dose)
and CI value of each pair of two drugs at their IC50s, and found
that the drug pair of BI-2536 and fasudil was in the leading rank
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and achieved satisfying Fa value in Fa–CI plot (Fig. 1b). BI-2536,
a selective inhibitor of PLK1, effectively inhibits different types of
tumour in phase II clinical trials. In addition, PLK1 gene was
identified as a synthetic lethal partner of RAS oncogene17.
Fasudil, a RhoA/Rho kinase (ROCK) inhibitor, has been
approved in Japan and China for treatment of cerebral
vasospasm, stroke and hypertension. Although the Fa values of
drug pairs of ABT-263 (Bcl-xL inhibitor) with irinotecan
(topoisomerase inhibitor) was higher than that of BI-2536/
fasudil, we collectively considered their drug target, clinical safety
and progression, and finally chose the drug pair of BI-2536 and
fasudil. Next, we extensively investigated the effects of combined
inhibition of the PLK1 and Rho signalling pathways on KRAS-
mutant cancers in vitro and in vivo.
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Figure 1 | A synthetic lethal chemical screen reveals that KRAS-mutant cells are selectively sensitive to the combined inhibition of PLK1 and ROCK.
(a) Schematic of the combinations tested and the drug interaction signatures. Twenty clinical drugs were tested in pairwise combinations (a total of 190
pairs) in T29Kt1 cells harbouring a KRAS mutation. Drugs were added at a relevant fixed ratios (IC50 ratios, see also Supplementary Table 1) at four
concentration combinations in each representative drug pair. The cell viability was determined. Left: compilation of the total number of drug pair synergies,
moderate synergies, nearly additive interactions and antagonistic interactions. The combination index (CI) was calculated using CalcuSyn software
(Version 2; Biosoft) as described in the Methods section. Right: the frequencies at which the drug target gene types appear in the synergy cluster (CIo1).
The oncogenic KRAS synthetic lethal genes accounted for the largest proportion of synergies specific to KRAS-mutant cells. (b) The Fa–CI plot. The Fa
(fraction affected by the dose) and CI value of two drugs at their combination of IC50’s were listed in X and Y axes and synergistic pairs with CIo1 were
shown. The combination of BI-2536 and fasudil exhibited leading therapeutic efficacy and applicable potential. (c) The cytotoxicity of BI-2536 and fasudil.
T29Kt1 and T29 cells were incubated with increasing concentrations of BI-2536 (BI) and fasudil (Fas) alone or in combination for 72 h, and the cell viability
was determined. The CI and Fa values for the combination of BI-2536 and fasudil were calculated. The averages and error bars represent the mean±s.d.
from three independent experiments. (d) Percentage of apoptotic cells was determined by Annexin-V and propidium iodide staining after BI-2536
(10 nmol l 1) and fasudil (40mmol l 1) treatment alone or in combination for 72 h in T29Kt1 and T29 cells.
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Compared with BI-2536 or fasudil alone, BI-2536 plus fasudil
exhibited enhanced cytotoxicity in T29Kt1 cells. The CI values
were all o0.7, indicating a strongly synergistic interaction
between BI-2536 and fasudil in KRAS-mutant cancer cells. In
contrast, this combination was antagonistic in KRAS wild-type
T29 cells (Fig. 1c). This combination consistently led to
significantly more apoptosis than either agent alone (Fig. 1d) in
T29Kt1 cells, as observed by an Annexin-V/propidium iodide
apoptosis assay. Synergy of combined inhibition of PLK1 and
ROCK was also got from another drug pair of BI-6727 and
Y-27632 (Supplementary Fig. 1). These results suggest that the
combined inhibition of PLK1 and ROCK is a novel regimen for
inhibiting KRAS-mutant cancer cells.
The inhibition of PLK1 and ROCK leads to enhanced toxicity.
To verify the synergistic effect of the synthetically lethal genes
PLK1 and ROCK, we evaluated a panel of cell lines from lung,
colon and pancreatic cancers in which a KRAS mutation is the
predominant oncogenic alteration3, as well as four normal human
cell lines (fibroblasts/epithelial cells; Supplementary Table 2).
Human cancer cell lines bearing KRAS mutations tended to be
more sensitive to either BI-2536 or fasudil than KRAS wild-type
ones (Fig. 2a; Po0.01 or Po0.001, Student’s t-tests). Intriguingly,
the combination of BI-2536 and fasudil at low doses led to a more
robust reduction of cell viability than either single agent alone in
KRAS-mutant, but not wild-type, cancer cells (Fig. 2b;
Supplementary Fig. 2a). More importantly, this drug pair had
minimal effects on normal human fibroblasts or epithelial cells
(Fig. 2b), indicating that the drug pair is directly cytotoxic in
cancer cells.
We next analysed the cell cycle distribution of H522 (KRAS
wild-type), A549 (KRAS-mutant) and H441 (KRAS-mutant) cells
after exposure to BI-2536/fasudil or either single drug alone. Our
results showed that BI-2536/fasudil led to a profound G2/M
arrest in KRAS-mutant cells but only modestly affected the cell
cycle profile of wild-type cells (Fig. 2c). Moreover, BI-2536/fasudil
induced marked apoptosis in KRAS-mutant A549 and H441 cells,
with a sevenfold increase in the number of apoptotic cells
compared with the untreated controls (Fig. 2d). A long-term
clonogenicity assay was then performed to assess whether BI-
2536 plus fasudil had the capacity to cause irreversible growth
arrest in KRAS-mutant cells. We observed a marked decrease in
colony number along with colony size in the combination group
(Fig. 2e). Taken together, these results suggest that this novel drug
pair can rather effectively inhibit the growth of a large proportion
of KRAS-mutant cancer cells of different tissue origins.
The p53 pathway is involved in the sensitivity of drug pair. To
identify the potential mechanisms that underlie the enhanced
activity of the combined PLK1 and ROCK inhibition, we con-
ducted a microarray analysis to examine the gene expression
profiles in KRAS-mutant A549 cells treated with BI-2536/fasudil
or vehicle control. The differentially expressed genes (DEGs) were
identified based on a false discovery rate threshold of 0.05.
Pathway enrichment analysis, an analysis that maps genes to the
KEGG pathways, revealed that the p53 signalling pathway had the
highest number of significantly upregulated genes (Fig. 3a). The
most statistically significant changes in the gene expression of the
p53 signalling pathway components were shown in the heatmap
(Fig. 3b). Important genes that are involved in the function of the
p53 pathway31, including CDKs, CDKN1A, ATM and others,
were highlighted. Both single agents led to the changes in gene
expression in different directions to some extent, but the
combination of BI-2536 and fasudil further enhanced these
gene expression patterns (Fig. 3b).
Oncogenic signalling networks typically exhibit crosstalk
between multiple signalling pathways, rendering single-protein
measurements ineffective in predicting complex cellular
responses to drugs32. To investigate the integrated regulatory
mechanism involved in the selectivity of BI-2536/fasudil, we
further performed transcription factor-binding site (TFBS)
enrichment analysis to predict the underlying TF network
based on our DEG profiles. The University of California Santa
Cruz genome browser (UCSC) TFBS conserved track
data33 were used to reduce the false positive rate in our
analysis (Supplementary Table 3). TFBS analysis suggests that
several TFs, such as p53, E2F and AP2, were activated by
BI-2536/fasudil, and that most of the DEGs that are targets of
these activated TFs, which is related to disease genes in
lung cancer (green) and non-small cell lung cancer (NSCLC;
blue) according to the MalaCards database (Fig. 3c). We
further analysed the protein–protein interaction networks
using data from the STRING database. The results showed that
the DEGs formed a densely connected network (Fig. 3d),
suggesting that these genes work as a functional module at the
protein level.
The inhibition of PLK1 and ROCK upregulates p21WAF1/CIP1.
On the basis of the results of the microarray analysis, we further
evaluated the effect of BI-2536/fasudil on the p53 signalling
pathway. While this combination had little impact on p53 protein
levels, it acutely increased the level of the cyclin-dependent kinase
inhibitor p21WAF1/CIP1 in KRAS-mutant T29Kt1 cells, but not in
the isogenic wild-type T29 cells (Fig. 4a). To further confirm the
differences of p21 messenger RNA (mRNA) expression in KRAS-
mutant and wild-type cells, we conducted quantitative PCR
(qPCR) analyses in these cells. We found that treated KRAS-
mutant cells had much higher levels of p21 compared to wild-
type ones (Fig. 4a). Similar effects were observed in A549 (KRAS-
mutant) and H522 (KRAS wild-type) cells; increased p21 protein
and mRNA expression predominantly occurred in KRAS-mutant
cells (Fig. 4b; Supplementary Fig. 2b).
Interestingly, we found that the level of the pro-apoptotic
protein BAX was increased, while CDK1 phosphorylation
(Tyr15) was decreased in KRAS-mutant cells in response to the
BI-2536/fasudil combination (Supplementary Fig. 2c). These
results agree with the model that p21 promotes G2/M cell cycle
arrest and apoptosis through BAX and CDK1 (ref. 34), and are
consistent with our earlier results (Fig. 2c,d). As expected, under
the same conditions, p53 protein levels were not apparently
affected in KRAS-mutant cells, and we therefore speculate that
the BI-2536/fasudil-mediated upregulation of p21 is independent
of p53.
To further verify our assumption, we used two KRAS-mutant
human colon cancer cell lines: HCT-116 cells, which have wild-
type p53 (p53þ /þ ) and a subline that is deficient in p53 (HCT-
116 p53 / ), to explore whether p21 activation was mediated by
p53 in response to BI-2536/fasudil. Western blotting showed that
p53 deficiency did not impair the BI-2536/fasudil-induced
upregulation of p21 (Fig. 4c). These results suggested that p21
plays an independent role in the efficacy of this combined
treatment in KRAS-mutant cells.
Because the growth inhibitory function of p21 is associated
with its nuclear localization34, we further investigated the
subcellular localization of p21 in response to drug treatments.
We analysed its protein expression in the cytoplasm and in the
nuclear extracts, and found that BI-2536/fasudil caused higher
expression and nuclear translocation of p21 in KRAS-mutant
A549 cells compared with either agent alone (Fig. 4d). Co-
treatment with BI-2536 and fasudil resulted in a significant
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increase in p21 nuclear accumulation and a marked decrease in
cytoplasmic p21 by immunofluorescence assays (Fig. 4e), which is
consistent with the data shown in Fig. 4d. In addition, the p21
nuclear shift mediated by the drug combination was consistent
with the observed survival inhibition in KRAS-mutant cells
(Fig. 2b).
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Figure 2 | KRAS-mutant cancer cells are significantly sensitive to the pharmacologic inhibition of PLK1 and ROCK. (a) Seventeen KRAS-mutant (KRAS
MUT) and nine wild-type (KRAS WT) cancer cell lines were treated with the indicated concentrations of BI-2536 or fasudil for 72 h; the dots represent the
cell viability normalized to no drug treatment. The bars indicate the means. Student’s t-tests were performed between the MUTand WTgroups; **Po0.01;
***Po0.001. (b) Thirty-two cell lines carrying different KRAS genotypes were treated with BI, Fas or the combination of BI and Fas for 72 h. The percentage
of viable cells was colour coded in a heatmap. (c) H522 (KRAS WT), A549 (KRAS MUT) and H441 (KRAS MUT) cells were treated with BI-2536
(2 nmol l 1), fasudil (10mmol l 1) or the combination (BI-2536þ fasudil) for 48 h after synchronization and release. The cell cycle distribution was
analysed by flow cytometry using propidium iodide staining. (d) A549 and H441 (KRAS MUT) cells were treated with BI-2536 (2 nmol l 1), fasudil
(10mmol l 1) or a combination of BI and Fas for 72 h, and the percentage of apoptotic cells (Annexin positive) was determined by Annexin-V and
propidium iodide staining. (e) A549 cells (1,000) were plated in 60-mm dishes and treated with dimethylsulphoxide, BI-2536 (2 nmol l 1), fasudil
(10mmol l 1) or a combination of BI and Fas for 7 days. The cell colonies were stained with crystal violet and counted. The relative number of colonies was
calculated by normalization to control as 100%. The values represent the mean±s.d. of three independent assays; Student’s t-tests were performed;
**Po0.01; ***Po0.001. MUT, mutant; WT, wild type.
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To confirm the significant role of p21 in the efficacy of BI-
2536/fasudil, we silenced p21 expression by RNAi and the
CRISPR/CAS9 system, and analysed its effects on the cell cycle
progression in KRAS-mutant cancer cells. As expected, knock-
down of p21 led to a significant attenuation of BI-2536/fasudil-
induced G2/M arrest (Fig. 4f), while total depletion of p21 led to a
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Figure 3 | The p53 signalling pathway is involved in the sensitivity of BI-2536/fasudil in KRAS-mutant cancers. (a) Pathway enrichment of the
differentially expressed genes in A549 cells after BI-2536þ fasudil treatment. For enrichment analysis, the subsets of upregulated genes were used. The
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arrows represent genes that are upregulated, and the blue arrows represent genes that are downregulated. TP53 and CDKN1A, primary members of this
pathway, are indicated. (c) Differentially expressed disease genes that are explained by enriched TF. Red node, TFs; blue node, non-small cell lung cancer-
related genes; green node, lung cancer-related genes. (d) Protein–protein interaction networks, functional modules consisting of the genes downstream of
the enriched TF.
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complete rescue of G2/M arrest mediated by the drug pair in
KRAS-mutant cancer cells (Fig. 4g). These findings unambigu-
ously assign a critical role for p21 in the combinatorial action.
Taken together, our results suggested that the growth inhibitory
effect of BI-2536/fasudil in cells carrying a KRAS mutation was
mediated by p53-independent p21 activation.
The in vivo therapeutic efficacy of BI-2536/fasudil. On the basis
of the broad efficacy of combined PLK1 and ROCK inhibition
against KRAS-mutant cells in vitro, we assessed the therapeutic
efficacy of this combination in a series of preclinical cancer
models in vivo.
First, we assessed the efficacy of combined PLK1/ROCK
inhibition in an acknowledged and widely used mouse model for
KRAS study, the LSL-KRASG12D mouse model (Fig. 5a, upper
left)35,36. After 12 weeks of cancer progression induced by
Adenovirus-Cre, mice were randomly treated with vehicle, BI-
2536, fasudil or combination of both the drugs for 4 weeks and
then measured by micro-computed tomography (Fig. 5a, lower
left). BI-2536/fasudil led to significantly greater tumour
regression compared with vehicle or either agent alone, with
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immunoblotting.
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near-complete abrogation of lung tumours in some cases (Fig. 5a,
right; Fig. 5b). Infected LSL-KRASG12D mice began to die on day
28 with a median survival of 41 days. Therapies with single drug
led to a modest survival advantage (median survival of 90 days in
BI-2536 group; median survival of 71.5 days in fasudil group).
Strikingly, the combined therapy led to much higher long-term
survival advantage (log-rank test; P¼ 0.0005; Fig. 5c).To facilitate
the translation of this novel drug pair into clinical settings, we
next tested the combination in a patient-derived tumour explant
(PDTX) model of lung cancer carrying an activating G12D KRAS
mutation. After 4-week treatment, the co-administration of BI-
2536 and fasudil led to a marked tumour growth inhibition
(Po0.0001, one-way analysis of variance followed by Bonferroni
multiple comparison test) compared with the vehicle or either
single agent alone, suggesting a strong synergy (Fig. 5d,e;
Supplementary Fig. 3a). The effect of this combination therapy
was quite durable, and all treatments were well tolerated because
no animals in these studies exhibited significant differences in
body weight between the groups (Supplementary Fig. 3b). Similar
results were observed in the A549 orthotopic lung cancer model
(Supplementary Fig. 3c–f). Overall, these results indicate that BI-
2536/fasudil has substantial preclinical in vivo efficacy in different
types of KRAS-mutant cancer models and provide a rationale for
this combination in clinical trials.
To further evaluate the mechanism that underlies the anti-
proliferative effects of this combination in vivo, PDTX tumour
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Figure 5 | In vivo efficacy of combined PLK1 and ROCK inhibition. (a) Left: schematic illustration of the LSL-KRASG12D allele and drug treatment protocol.
Established lung tumours in LSL-KRASG12D mice were treated with vehicle, BI-2536 (BI), fasudil (Fas) or both drugs in combination (BIþ Fas). Right: after 4
weeks treatment, animals were scanned by micro-computed tomography and representative transverse images are shown. Red arrows indicate lung
tumours. (b) Mean tumour volume at the end point of the indicated treatments. Each dot represents an individual mice (n¼ 5 per group). Data represent
the mean±s.e.m. *Po0.05; **Po0.01; ***Po0.001 by one-way analysis of variance (ANOVA) followed by Bonferroni multiple comparison test. (c) The
survival rate was calculated by Kaplan–Meier method (n¼6 per group). Statistical significance was assessed by log-rank tests, *Po0.05; **Po0.01;
***Po0.001. (d) The growth of primary NSCLC tumour xenografts (n¼ 8 per group). Data represent the mean±s.e.m. *Po0.05; **Po0.01; ***Po0.001
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28. Each dot represents a tumour from an individual mouse. Data represent the mean±s.e.m. *Po0.05; **Po0.01; ***Po0.001 by one-way ANOVA
followed by Bonferroni multiple comparison test. (f) p21 mRNA expression in the primary NSCLC tumour xenografts. Each dot represents a tumour from an
individual mouse (n¼ 6 per group). Data represent mean±s.e.m. *Po0.05; **Po0.01; ***Po0.001 by one-way ANOVA followed by Bonferroni multiple
comparison test. (g) p21 protein level in the lysates from the tumours in the primary tumour xenograft mice. Each number represents a tumour from an
individual mouse. See also Supplementary Fig. 3.
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samples were collected for qPCR and immunoblotting analyses.
Consistent with the results in tumour cells in vitro, the
combination of BI-2536 and fasudil led to significant increases
in the mRNA and protein expression of p21 in PDTX tumours
(Fig. 5f,g). These findings supported the hypothesis that the
efficacy of BI-2536/fasudil in KRAS tumour regression was
mediated by p21 activation.
The overexpression of p21WAF1/CIP1 impairs KRAS-mutant
cancer. Our results strongly indicated that tumour cells and
xenografts with activated KRAS relied on suppressing p21 activity
for growth. We hypothesized that there is a synthetic lethal
interaction between p21 and KRAS, and that the elevated
expression of p21 would suppress KRAS-mutant cancers. Initial
support for this hypothesis came from an analysis of the effects of
p21 overexpression on the survival of KRAS-mutant and wild-
type cells. Intriguingly, our data showed that the overexpression
of p21 by transfection with a p21 complementary DNA (cDNA)
plasmid led to an apparent inhibition of cell viability in KRAS-
mutant T29Kt1 cells but not in their KRAS wild-type counter-
parts (Fig. 6a). The overexpression of p21 induced marked cell
apoptosis in KRAS-mutant T29Kt1 cells (Fig. 6b). We then
extended these studies to a panel of cancer cell lines. Similar
results were observed; cells harbouring KRASmutations tended to
be much more sensitive to p21 overexpression than cells with
wild-type KRAS (Fig. 6c; Po0.0001, Student’s t-tests).
Several anticancer agents exert their function, in part, through
the induction of p21, such as histone deacetylase inhibitors and
statins34,37. We further assessed the impact of SAHA, a histone
deacetylase inhibitor, on KRAS-mutant cancer cells. SAHA
selectively inhibited KRAS-mutant cells (Fig. 6d). In summary,
our data supported the hypothesis that p21 activation could serve
as a synthetic lethal factor in KRAS-mutant cancer cells and that
p21 itself may be a novel therapeutic target for cancers with KRAS
mutations.
Discussion
Although KRAS is commonly mutated in human cancers,
targeted therapies for these refractory cancers remain a major
clinical challenge. Innovative approaches have recently been
developed using small molecules to impair the interaction
between KRAS and PDEd or effectors9,38, but these molecules
are a long way from use in the clinic. Mutant KRAS persistently
and directly activates both RAF and PI3K, which has led to the
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exponential growth of studies aiming to treat KRAS-mutant
tumours by coordinately inhibiting both of these pathways39.
Unfortunately, the toxicity of this combination restricts its clinical
applicability8,23. In recent years, synthetic lethal analyses have
made another big splash and successfully uncovered multiple
non-oncogene addiction pathways that were required for the
survival of RAS-mutant cells17,20. Although the functions of most
KRAS synthetic lethal genes have not been systematically
validated, the potential utility of these genes is promising18. As
a complementary approach, synthetic lethal chemical screening
opens a new avenue for the therapeutic treatment of KRAS-
transformed tumours. More importantly, it provides a shortcut
and affords easy translational strategies utilizing drugs that are
already in clinical use.
In this study, we conducted a synthetic lethal chemical
screening and a combinatorial strategy to identify novel drug
pairs that would effectively kill KRAS-mutant cancers. Our
screening revealed 65 combination hits with a CIo1. Because a
CIo0.7 depicts a strong synergy, this cluster of hits was further
analysed. Although the number of agents in each RAS-related
catalogue was relatively small in our screening program, several
previously reported synergistic combinations for the treatment of
KRAS-driven cancers were confirmed, such as the combined
inhibition of MEK and PI3K39 (CI¼ 0.59 at median effective
dose), the combined inhibition of BCL-XL and MEK23 (CI¼ 0.68
at median effective dose), the combined inhibition of Hsp90 and
MEK40 (CI¼ 0.03 at median effective dose) and the combined
inhibition of MEK and AKT41 (CI¼ 0.77 at median effective
dose), which was recently set for a clinical trial (Trial NCT
number NCT01021748). This synergistic cluster of CIo0.7 also
included previously described combination strategies in cancer
therapy regardless of KRAS status, such as the combination of
topoisomerase inhibitors with tyrosine kinase inhibitors42,43 or
mTOR inhibitors44 in different cancer models. Importantly, our
screening strategy also identified previously undescribed drug
interaction patterns and several novel combinations with high
efficacy against KRAS-mutant cancers, for example, the combined
inhibition of PLK1 and ROCK (CI¼ 0.33 at median effective
dose). We classified the gene types in the synergy hits (CIo1;
Fig. 1a) and found that 71% of the combinations contained drugs
whose targets were synthetic lethal genes of oncogenic KRAS,
suggesting that RAS-transformed cells relied heavily on additional
signalling contexts for survival. These findings are fully supported
by the concept of non-oncogene addictions in cancer cells5, which
provides the rationale for developing synthetic lethality-based
anti-RAS therapy.
Given the importance of synthetic lethal genes in buffering the
effect of changes in KRAS, combinations of inhibitors that target
these genes may be promising strategies to treat recalcitrant
KRAS-mutant cancers. In our combinatorial screening, combined
PLK1/ROCK inhibition with BI-2536 and fasudil emerged as a
top hit and exhibited a strong ability to induce apoptosis and cell
cycle arrest in KRAS-mutant cancer cell lines. Importantly, this
combination produced potent tumour regressions in a series of
KRAS-mutant lung cancer models in vivo, such as LSL-
KRASG12D mouse model and PDTX models, as well as orthotopic
lung cancer models (Fig. 5; Supplementary Fig. 3). Specially, this
drug pair markedly increased the survival rate of LSL-KRASG12D
mice as compared with either single agent alone, suggesting an
encouraging therapeutic window. BI-2536 and fasudil are already
being used in clinical trials17,20, the single agents or dual agents at
the doses tested in this study were well tolerated, and no gross
toxicity was observed in the tumour-bearing mice. Our findings
increase the likelihood that the coordinate inhibition of synthetic
lethal genes of oncogenic KRAS may provide a novel therapeutic
approach for treating these recalcitrant cancers. Further study of
this type of combination (for example, the dual inhibition of
PLK1 and ROCK) against KRAS-mutant cancers in clinical trials
may be warranted.
Microarray profiling revealed that the p53 signalling pathway
was implicated in the synergistic efficacy of BI-2536/fasudil. The
expression of p21, a key target gene of p53, was examined in
treated cells and primary tumour xenografts. Intriguingly, we
found that BI-2536/fasudil significantly elevated the expression of
p21 in vitro and in vivo, but p21 activation was independent of
the TF p53. These data were not paradoxical because p21, a
critical cell cycle regulator, can be induced by p53-dependent and
-independent mechanisms. Consistent with this, TFBS enrich-
ment analysis revealed that, in addition to p53, TFs such as
CREB, AP2, p300, E2F and STAT1 were all involved in the
mechanism of this drug pair (Fig. 3c). These TFs have been
reported to induce CDKN1A transcription in a p53-independent
manner34. Notably, this combination did not affect the
phosphorylation of AKT and ERK (Supplementary Fig. 2c),
further indicating that it probably targeted a synthetic lethal
dependency of mutant KRAS, rather than RAS downstream
effectors. p21 depletion rendered cells resistant to the
combination treatment (Fig. 4f,g), indicating that p21 operates
orthogonally to the oncogene RAS. Synthetic lethal interactions
have been most commonly described for loss-of-function alleles,
and they may also involve gain-of-function alleles45. The concept
of ‘synthetic dosage lethality’ was proposed to identify genetic
interactions by the overexpression of a particular reference gene
in the background of a target mutation46. On the basis of this
concept, CDKN1A (p21) and KRAS are considered to be
‘synthetic lethal’ because the overexpression of CDKN1A
combined with a mutation in KRAS resulted in a lethal
phenotype in our system. Previous genome-wide studies17,20 to
uncover KRAS synthetic lethality did not identify CDKN1A as a
synthetic lethal gene in KRAS-mutant cancer, primarily because
those screens were based on the loss-of-function interference
rather than gain-of-function phenotypes. Since p21 protein plays
an important role in tumour suppression, targeting p21 or factors
that regulate its activity is a promising therapeutic strategy34,37. In
this study, we revealed for the first time that p21 is a novel
synthetic lethal candidate of oncogene KRAS. Overexpression of
p21 by cDNA or drugs selectively killed KRAS-mutant cells
(Fig. 6), suggesting that p21 is a potential target for the treatment
of KRAS-mutant cancer.
Our results are, to some extent, consistent with previous
findings that KRAS-mutant cells showed a particular dependence
on genes implicated in mitotic functions, such as PLK1 (ref. 17),
components of the anaphase-promoting complex17, CDC2/CDK1
(ref. 47) and CDC6 (ref. 21). Mutations in oncogenes, such as
RAS, have been suggested to contribute to chromosome instability
and cause mitotic stress, and slight disturbances in cell cycle
regulation may therefore have a serious impact on survival5,48.
The CDK inhibitor p21 is implicated in cell mitotic regulation
due to its ability to stabilize CDK–cyclin complexes and
proliferating cell nuclear antigen34. In this study, the
combination of BI-2536 and fasudil markedly induced p21
expression. As a result of p21 induction, mitotic stress was
augmented in KRAS-mutant cancers, and this stress may cause
the observed susceptibility to apoptosis in KRAS-mutant cancers.
In summary, we developed a combinatorial drug screening
based on synthetic lethality to identify novel combination
partners for the treatment of KRAS-driven cancers. Our study
revealed a preclinical rationale for exploring a synthetic lethal
regimen that combined the inhibition of PLK1 and Rho signalling
to conquer KRAS-mutant cancer. The activity of this drug pair
was mediated by activating p21, and CDKN1A (p21) was further
identified as a new ‘synthetic lethal partner’ of KRAS. Our new
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combination strategy defined by targeting the synthetic lethal
partners of the oncogene KRAS may warrant further clinical
investigation.
Methods
Cell lines and culture. The immortalized human ovarian surface epithelial cells
T29 and their transformed counterparts T29Kt1 (with the introduction of
KRASV12 into the immortalized cells) were reported previously28 and were
cultured in medium consisting of 1:1 MCDB105 medium and M199 medium
(Sigma-Aldrich Co.) with 10% fetal bovine serum (HyClone) in the presence of 1%
penicillin and streptomycin (HyClone). HCT-116 (p53þ /þ ) and HCT-116
(p53 / ) were kindly provided by Dr Chuangui Wang (East China Normal
University, Shanghai, China) and were maintained in DMEM with the same
supplements. The culture medium of other cells used is listed in Supplementary
Table 2. A549, H441, H358, H1299, H1975, PC9, H661, H522, HCT-15, LoVo,
SW480, SW620, DLD-1, HT29, CaCo2, HCT-8, CCD-18Co, CCD841CoN, Panc-1,
CFPAC-1 and BxPC-3 were obtained from the American Type Culture Collection
(Manassas, VA, USA); Calu-1, Calu-3, WI-38, MRC-5, T84, LS174T, SW1116 and
AsPC-1 were obtained from the Shanghai Cell Bank of the Chinese Academy of
Sciences (Shanghai, China). KRAS status identification by sequencing and limited
genotyping in cancer cells was shown in Supplementary Table 2. Most of these cells
were grown at 37 C under a humidified 95:5 (%; v/v) mixture of air and CO2.
SW480 and SW620 cells were grown without CO2. All of the cell lines were
authenticated by short tandem repeat analysis.
Cell viability assays. Cells were plated at a density of 2,000–5,000 cells per well in
96-well plates and allowed to adhere overnight, and subjected to drug treatment for
72 h. Cell viability was determined using CellTiter 96 AQueous One Solution from
Promega according to the manufacturer’s instructions. The half inhibitory con-
centration IC50 values were calculated by Prism 5 (GraphPad Software). The drug
combinations were performed with fixed drug ratios (that is, the IC50 ratio), and
the CI equation as described by Chou-Talalay49,50 was generated using CalcuSyn
software (Version 2; Biosoft). Combinations with CIso1 were considered to be
synergistic. The following small inhibitors were used (Supplementary Table 1):
sorafenib (Cat. #S7397), selumetinib (AZD6244, Cat. #S1008), perifosine (Cat.
#S1037), rapamycin (Cat. #S1039), NVP-BEZ235 (Cat. #S1009), gefitinib (Cat.
#S1025), axitinib (Cat. #S1005), sunitinib (Cat. #S7781), PD0332991 (Cat. #S1116),
BI-2536 (Cat. #S1109), BX-795 (Cat. #S1274), BAY 11–7082 (Cat. #S2913),
bortezomib (Cat. #S1013), fasudil (Cat. #S1573), ABT-263 (Cat. #S1001), BI-6727
(Cat. #S2235), Y-27632 (Cat.#S1049) and SAHA (Cat. #S1047) were obtained from
Selleck Chemicals. Irinotecan (Cat. #I1406) and topotecan (Cat.#T2705) were
obtained from Sigma. Wortmannin was obtained from Calbiochem/Merck
(#681676). 17AAG was obtained from Invivogen (#ant-agl-5). 3-BrPA was
obtained from TCI (#M2223).
Apoptosis. Cells were seeded in six-well plates and treated with the indicated
treatments for 72 h. The apoptosis assays were conducted using the BD Pharmingen
Apoptosis Detection Kit (BD) and analysed by flow cytometry (FACSCalibur, BD).
Cell cycle analysis. Exponentially growing cells were incubated with 80–
100 ngml 1 of nocodazole (Sigma) for 16h to synchronize the cell cycle. The
synchronized cells were exposed to the indicated treatments for 48 h. The cells were
then fixed with 70% ethanol overnight, permeabilized with 0.1% Triton X-100, and
incubated with Ribonuclease A (RNase A; Takara biotechnology Co.) and propidium
iodide (Sigma). The cell cycle was analysed by flow cytometry (FACSCalibur, BD).
Two-dimensional clonogenic assay. A549 cells were plated at a density of 1,000
cells per well in six-well plates. After cell attachment, medium containing treatment
was added and changed every 3 days for a period of 1 week. The colonies were fixed
in 4% paraformaldehyde and stained with 0.5% crystal violet. Photographs were
taken, and clones were counted if they contained 450 viable cells.
RNA isolation and microarray analysis. A549 cells were treated with BI-2536
(4 nM), fasudil (20 mM) or the combination of BI-2536 and fasudil for 6 h. Samples
were obtained from three independent biological replicates. Total RNA was isolated
using RNAiso plus (TaKaRa) according to the manufacture’s protocol. A total of
10mg purified RNA from each sample was submitted to the Gene Tech Company
Limited (Shanghai, China) for labelling and hybridization using Affymetrix Gen-
eChip PrimeView Human Gene Expression array (Affymetrix). The microarray
data discussed in this article have been deposited in National Center for Bio-
technology Information Gene Expression Omnibus (GEO) and are accessible
through (GEO) Series accession number GSE60887 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE60887).
Microarray data analysis. The robust multi-array average algorithm51
implemented in the Affymetrix Expression Console was applied on the raw
intensity data to perform the inter-chip normalization. The moderated t-test52 in
the limma package was then used to select the DEGs. The raw P values of results
were corrected for multiple testing by BH method53.
To predict the activated TFs under the experiment condition, the TFBS
enrichment analysis was performed as follow: let k denote the number of DEGs in p
expressed genes. We count the total number X of TFBS for the TF a from all the
promoter regions of the k DEGs. We randomly picked up k genes from p expressed
genes and counted the number x of TFBS for the same TF a, this procedure was
repeated n times. The significance of the TFBS enrichment analysis for the TF was
defined as:
P value ¼ # x  Xf g
n
ð1Þ
The TFBS data from the UCSC TFBS conserved track were used in this study and n
was set to 105 to accurately estimate the P value. The promoter region was defined
as the  5- to 1-kb region relative to the transcription start site.
Western blotting and antibodies. Western blotting was performed using stan-
dard methods. After being treated with indicated drugs, whole-cell or tumour tissue
extracts were prepared by radioimmunoprecipitation assay buffer (150mM sodium
chloride, 50mM Tris pH 8.0, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
SDS) supplemented with 10mM NaF, 1mM Na3VO4, 5mM EDTA, 1mM EGTA,
5 mgml 1 leupeptin, 1 mgml 1 pepstatin A, 1mM phenylmethylsulfonyl fluoride,
and protease and phosphatase inhibitor cocktail (Calbiochem). The cytoplasmic
and nuclear extracts were prepared as previously described based on the different
concentration of NaCl (ref. 54). Lysates were centrifuged at 12,000 r.p.m. for
20min at 4 C. Protein concentration of the supernatants was determined using a
BCA protein Assay Kit (Thermo Scientific). Equal amounts (30–50 mg) of the
proteins were resolved by 8–12% SDS–polyacrylamide gel electrophoresis gels and
transferred to nitrocellulose membranes (Millipore). Membranes were blocked in
5% bovine serum albumin for 1 h at room temperature, and then incubated with
specific antibodies for different western blot analyses at 4 C overnight. The bound
primary antibodies were detected by secondary conjugates compatible with infra-
red detection at 700 and 800 nm, and membranes were scanned using the Odyssey
Infrared Imaging System (Odyssey, LI-COR). Representative blots are shown from
several experiments. The relative optical density of blotting bands was quantified by
Image J software (NIH, Bethesda, MD, USA) and normalized to the control.
The following antibodies were used in these assays, all diluted in Primary
Antibody Dilution Buffer (Beyotime Biotechnology,China): antibodies directed
against p53 (#9282), Pan-ERK (#9102), Pan-AKT (#9272), Histone H3 (#4499,
1:2,000 dilution), a-tubulin (#2125), Phospho-CDK1 (at Tyr15 site, #4539),
Phospho-AKT (at Ser473 site, #9271) and Phospho-ERK (at Thr202/Tyr204
sites,#4376) were obtained from Cell Signaling Technologies (1:1,000 dilution).
Antibodies directed against p21 (ab109520, 1:2,000 dilution) and BAX (ab32503,
1: 2,000 dilution) were obtained from Abcam. Anti-b-actin antibody was purchased
from Sigma (A5441, 1:10,000 dilution). Secondary antibodies were from LI-COR
Biosciences, including IRDye 800CW Goat anti-Mouse IgG (926–32210, 1:10,000
dilution) and IRDye 800CW Goat anti-Rabbit IgG (926–32211, 1:10,000 dilution).
Uncropped blots are shown in Supplementary Fig. 4.
RT–PCR and quantitative real-time PCR. The total RNA was isolated with
RNAiso plus (TaKaRa). One microgram of total RNA was used for the synthesis of
first-strand cDNA using the PrimeScript RT reagent kit (TaKaRa). Reverse
transcription–PCR (RT–PCR) was performed in a 20-ml reaction mixture con-
taining cDNA (1 ml), forward and reverse primers (200 nM each), dNTP (250 mM),
10 PCR buffer (2ml) and 0.2 ml of TaKaRa Taq (TaKaRa). The amplified DNA
fragments were electrophoresed on an agarose gel. Quantitative real-time PCR was
performed according to the manufacturer’s instructions of the SYBR Premix Ex
Taq kit (TaKaRa) on an Mx3005P thermal cycler (Stratagene). The forward and
reverse primers for CDKN1A (p21) were as follows: forward, 50-TGTCCGTCA-
GAACCCATGC-30 and reverse, 50 -AAAGTCGAAGTTCCATCGCTC-30 ; b-actin:
forward, 50-AGCCGTGTTCTTTGCACTTT-30 and reverse, 50-AGGAAG-
GAAGGCTGGAAGAG-30.
siRNA experiments. A549 cells were plated in six-well plates and allowed to
adhere for 24 h. For transfection, 6 ml of Lipofectamine TM 2000 reagent
(Invitrogen) was added to 80 nM p21 small interfering RNA (siRNA) or negative
control siRNA in a final volume of 1ml culture medium. After 36 h of transfection,
cells were either treated with the appropriate drug for cell cycle assay or lysed for
immunoblotting to determine the efficiency of the knockdown. The siRNA for p21
and the negative control siRNA were synthesized and purified by GenePharma
(Shanghai, China). The two siRNA sequences for human p21 used in this study
were 50-GAUGGAACUUCGACUUUGUUU-30 (p21 siRNA-1) and 50-GGACA-
CAAAACCAGAGUUA-30 (p21 siRNA-2).
Construction of p21 knockout cell lines. The SpCas9 targeting vector lenti-
CRISPR v2 was purchased from Addgene (Cambridge, MA). For sgRNA cloning,
the lentiCRISPR v2 vector was digested with BsmBI and ligated with BsmBI-
compatible annealed oligos. SgRNA (50-CCGCGACTGTGATGCGCTAA-30) was
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designed using Optimized CRISPR Design. Lentiviruses were produced by co-
transfection of 293T cells with lentiviral backbone constructs (lentiCRISPR v2) and
packaging vectors (pMD2.G and pSPAX2) using Lipofectamine 2000 following to
the manufacturer’s protocols. Supernatant was collected 48 h post transfection and
added to HCT-116 cells in a six-well plate. Infected cells were selected with pur-
omycin, and single-cell clones with frame-shift mutation of P21 were chosen.
Transfection of p21 expression plasmid. pcDNA 3.1 expression vectors encoding
human p21WAF1/CIP1 were obtained from Dr Xiaotao Li (East China Normal
University, Shanghai, China). This plasmid, along with an empty vector control
were transfected into a panel of cell lines using Lipofectamine TM 2000 reagent
(Invitrogen) according to the manufacturer’s instructions. After 48 h of transfec-
tion, cell viability was measured using CellTiter 96 AQueous One Solution from
Promega (Madison, WI) as described above. Transfected cells were either con-
ducted for RT–PCR assay to determine the efficiency of the overexpression. Cell
lines used in this section were as follows: T29Kt1, A549, H441, Calu-1, HCT-116,
LS174T, HCT-15, SW480 and SW680 cells carrying KRAS mutation; and T29,
H522, H661, H1975, CaCO2, HT29, HCT-8 and BXPC-3 cells harbouring wild-
type KRAS.
Immunofluorescence assay. The nuclear translocation of p21 was examined by
immunofluorescence. A549 cells were plated on glass coverslips and treated with
indicated drugs. The cells were then fixed with 4% paraformaldehyde and per-
meabilized with 0.2% Triton X-100. The cells were washed in PBS, blocked and
incubated with p21 antibody (1:200 dilution) at 4 C overnight. After that the cells
were incubated with goat anti-rabbit IgG-FITC secondary antibody for 1 h, stained
with rhodamine–phalloidin (Molecular Probes) for 1 h and then counterstained for
the nuclei with DAPI (50 ngml 1) for 5min. The images were acquired using a
laser confocal microscope (Leica TCS SP5).
Animal studies. C57BL/6 and BALB/cA nude mice used in the present study were
purchased from National Rodent Laboratory Animal Resources (Shanghai, China).
Animals were caged in the groups of five in a laminar airflow cabinet under specific
pathogen-free conditions, fed with sterilized food and water, and kept on a 12-h
light/dark cycle. All treatments were administered according to the guidelines of
Institution Animal Care and Use Committee and all the protocols were approved
by East China Normal University.
LSL-KRASG12D mice in a C57BL/6 background were purchased from the
Jackson Laboratory (#008179; Sacramento, CA). These mice were crossed with
wild-type C57BL/6 mice to yield sufficient genotype verified LSL-KRASG12D mice.
To activate KrasG12D in mouse lung, intranasal administration of Ad-Cre was
performed as described35,36. Briefly, the verified 6-week-old male LSL-KRASG12D
mice were anaesthetized with isoflurane via a gas chamber. Ad-Cre (purchased
from HanBio, Shanghai, China) at the dose of 5 107 plague-forming unit in a
total volume of 125 ml and add 2M CaCl2 to obtain a final concentration of 10mM
as coprecipitates. Ad-Cre nasally is delivered by using two 62.5-ml instillations with
a 5-min interval. BI-2536 was dissolved in 0.1N HCl per saline at 20mg kg 1 and
delivered intravenously under a twice per week schedule. Fasudil was dissolved in
sterile water and delivered daily by oral gavage at a dosage of 50mg kg 1. Mice
were treated with indicated drugs or vehicles for 4 weeks and then measured by
micro-computed tomography (PerkinElmer, Waltham, MA). The survival rate was
calculated by Kaplan–Meier method. Statistical significance was assessed by log-
rank tests.
The primary KRAS-mutant lung cancer mouse model was established as
previously described55. Surgical samples of patient primary NSCLC presenting
adenocarcinoma histology were obtained from treatment-naive patients at the
Shanghai Changzheng Hospital (Shanghai, China). Prior written informed consent
was obtained from all patients, and the study protocol was approved by the
Shanghai Changzheng Hospital (Shanghai, China) ethics committee. In brief,
surgically removed tumour tissues were cut into fragments of B15mm3 and
implanted using a trocar needle subcutaneously into two to three male NOD/SCID
mice (5–6-week old) within 2 h. Transplanted mice bearing xenografts were
observed weekly. When tumour volume reachedB1,000mm3, primary xenografts
at the exponential growth phase were removed by serially passage to other 5–6-
week-old male BALB/cA nude mice. After three consecutive mouse-to-mouse
passages, the xenograft was considered to be stabilized and submitted to mutation
analyses to verify that it consistently maintained clinical NSCLC molecular
features. ‘Hot spot’ mutations in EGFR (exons 18, 19 and 21), KRAS
(exons 2 and 3), PIK3CA (exons 9 and 20) and BRAF (exon 15) were screened by
direct sequencing. Numerous samples from early passages were immediately stored
in liquid nitrogen and used for further experiments. Xenografts at passage 3 were
used in this study. Tumours were grown until up to 250mm3 before treatments.
Mice were treated using the same conditions as in the LSL-KRASG12D mouse
model. Tumour size was measured by calipers every other day and the body weight
was measured in parallel. Volumes were determined by the formula:
volume¼ lengthwidth2 0.52. On day 28, 2 h following the final dosing, the
mice were killed and tumour tissue was excised, weighed and snap-frozen in liquid
nitrogen for western blotting and qPCR analysis.
Statistical analysis. The data are presented as the mean±s.d. unless otherwise
stated. Statistical tests were performed using Microsoft Excel and GraphPad Prism
Software version 5.0. For comparisons of two groups, a two-tailed unpaired t-test
was used. For comparisons of multiple groups, one-way analysis of variance was
used. A Log-rank test was performed for survival curves. The levels of significance
were set at Po0.05 (*), Po0.01 (**) and Po0.001 (***). The specific tests applied
are included in the figure legends.
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